<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nxera Pharma Co., Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/nxera-pharma-co-ltd</link>
    <description>Latest news and press releases for Nxera Pharma Co., Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 01 May 2026 06:36:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nxera-pharma-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d621cabeedb30cb6fc2e17.webp</url>
      <title>Nxera Pharma Co., Ltd.</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd</link>
    </image>
    <item>
      <title>Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-operational-highlights-and-consolidated-results-for-the-first-quarter-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-operational-highlights-and-consolidated-results-for-the-first-quarter-2026</guid>
      <pubDate>Fri, 01 May 2026 06:36:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 1 May 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2026. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “We delivered strong momentum across the business in the first quarter of 2026. In our Japan and APAC commercial operations, this was highlighted by our important agreement with Santhera to</description>
    </item>
    <item>
      <title>Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/santhera-pharmaceuticals-full-year-results-for-the-year-ended-31-december-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/santhera-pharmaceuticals-full-year-results-for-the-year-ended-31-december-2025-1</guid>
      <pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release AGAMREE® delivers strong growth as global expansion accelerates Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2025. Dario Eklund, CEO of Santhera, said: “Our strong performance in 2025 reflects the continued momentum of AGAM</description>
    </item>
    <item>
      <title>Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-usdollar10-million-milestone-payment-from-abbvie-under-collaboration-targeting-neurological-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-usdollar10-million-milestone-payment-from-abbvie-under-collaboration-targeting-neurological-diseases</guid>
      <pubDate>Mon, 20 Apr 2026 06:30:00 GMT</pubDate>
      <description>This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipelineUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&amp;D milestone under its multi-target dis</description>
    </item>
    <item>
      <title>Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/notice-of-issuance-of-new-shares-in-connection-with-the-introduction-of-the-employee-stock-ownership-plan-matters-relating-to-stock-units-and-determination-of-payment-amount-and-other-matters-of-issuance-of-new-shares-under-prior-rsu-award</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/notice-of-issuance-of-new-shares-in-connection-with-the-introduction-of-the-employee-stock-ownership-plan-matters-relating-to-stock-units-and-determination-of-payment-amount-and-other-matters-of-issuance-of-new-shares-under-prior-rsu-award</guid>
      <pubDate>Wed, 15 Apr 2026 06:34:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 15 April 2026 – Nxera Pharma Co. Ltd (“Nxera” or the “Company”; TSE 4565) announces that, in connection with the introduction of the Employee Stock Ownership Plan for employees residing in Japan (“J-ESOP”), as announced on 19 November 2025, it has resolved to issue new shares of the Company (the &quot;J-ESOP Share Issuance&quot;) as set out below. The J-ESOP Share Issuance is intended to secure the shares required for the operation of J-ESOP, including in connection with th</description>
    </item>
    <item>
      <title>Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharmas-quviviqr-daridorexant-25mg-and-50mg-receives-approval-in-taiwan-for-the-treatment-of-insomnia</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharmas-quviviqr-daridorexant-25mg-and-50mg-receives-approval-in-taiwan-for-the-treatment-of-insomnia</guid>
      <pubDate>Tue, 14 Apr 2026 08:43:00 GMT</pubDate>
      <description>Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ® is approved through Taiwan’s Streamlined Review Designation pathway Tokyo, Japan and Cambridge, UK, 14 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical distribution and commercialization company based in Taipei, Taiw</description>
    </item>
    <item>
      <title>Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharmas-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia-1</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharmas-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia-1</guid>
      <pubDate>Sun, 12 Apr 2026 23:30:00 GMT</pubDate>
      <description>NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineNxera to receive US$22.5 million in milestone payments from Neurocrine Tokyo, Japan and Cambridge, UK, 13 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated and dosed the first patient(s) i</description>
    </item>
    <item>
      <title>Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-achieves-second-development-milestone-in-collaboration-with-eli-lilly-targeting-metabolic-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-achieves-second-development-milestone-in-collaboration-with-eli-lilly-targeting-metabolic-diseases</guid>
      <pubDate>Wed, 08 Apr 2026 23:34:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 09 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requir</description>
    </item>
    <item>
      <title>Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharmas-partner-centessa-pharmaceuticals-to-be-acquired-by-lilly</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharmas-partner-centessa-pharmaceuticals-to-be-acquired-by-lilly</guid>
      <pubDate>Tue, 31 Mar 2026 23:43:00 GMT</pubDate>
      <description>Lilly to gain ownership of Centessa&apos;s OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in its future development and commercialization Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entere</description>
    </item>
    <item>
      <title>Full Year 2025 Trading Update</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/full-year-2025-trading-update-8</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/full-year-2025-trading-update-8</guid>
      <pubDate>Thu, 12 Mar 2026 06:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2025. Dario Eklund, CEO of Santhera, said: “The strong commercial momentum we are seeing with AGAMREE® reflects growing adoption across our core European markets and through our global partners, expanding access for more patients with Duchenne</description>
    </item>
    <item>
      <title>Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-usdollar3-million-milestone-payment-from-centessa-pharmaceuticals</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-usdollar3-million-milestone-payment-from-centessa-pharmaceuticals</guid>
      <pubDate>Thu, 05 Mar 2026 08:03:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research col</description>
    </item>
    <item>
      <title>Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-submits-marketing-authorization-application-for-daridorexant-in-south-korea</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-submits-marketing-authorization-application-for-daridorexant-in-south-korea</guid>
      <pubDate>Wed, 04 Mar 2026 08:54:00 GMT</pubDate>
      <description>Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO) Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Com</description>
    </item>
    <item>
      <title>Nxera Pharma Proposes Changes to its Board of Directors</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-proposes-changes-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-proposes-changes-to-its-board-of-directors</guid>
      <pubDate>Fri, 13 Feb 2026 10:34:00 GMT</pubDate>
      <description>Mr. Takeo Morooka nominated for appointment as new External DirectorMs. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated below. The nomination of candidates for External Directors is based on the resolution of the Nomination Committee. The appointments are expected to be ratified</description>
    </item>
    <item>
      <title>Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-operational-highlights-and-consolidated-results-for-the-fourth-quarter-and-full-year-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-operational-highlights-and-consolidated-results-for-the-fourth-quarter-and-full-year-2025</guid>
      <pubDate>Fri, 13 Feb 2026 06:37:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2025. The full report can be viewed here. Christopher Cargill, President and CEO of Nxera Pharma, commented: “2025 was a year of disciplined execution and strategic progress for Nxera, as we continued to build a more focused, resilient and scalable bio</description>
    </item>
    <item>
      <title>Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-dollar18-million-milestone-payment-from-centessa-pharmaceuticals</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-dollar18-million-milestone-payment-from-centessa-pharmaceuticals</guid>
      <pubDate>Thu, 12 Feb 2026 08:45:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboratio</description>
    </item>
    <item>
      <title>Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-licenses-gpcr-targeted-program-to-newly-founded-spin-out-company</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-licenses-gpcr-targeted-program-to-newly-founded-spin-out-company</guid>
      <pubDate>Thu, 12 Feb 2026 08:38:00 GMT</pubDate>
      <description>New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly established independent company (the “NewCo”), created by a leading international life sciences investment firm, to advance Nxera’s G protein-coupled receptor (GPCR)-targeted program (the “Program”). Under the Agreement, Nx</description>
    </item>
    <item>
      <title>Nxera Pharma Webinar Presentation for FY2025 Financial Results</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-webinar-presentation-for-fy2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-webinar-presentation-for-fy2025-financial-results</guid>
      <pubDate>Mon, 26 Jan 2026 10:00:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 26 January 2026 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2025 on Friday, 13 February 2026. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Patrik Foerch. CSO and President of Nxera Pharma UK and Toshi Maeda, COO and President of Nxera Pharma Japan, at 5:00 pm JST (8:00 am GMT) on Friday, 13 February</description>
    </item>
    <item>
      <title>Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-establishes-metabolic-advisory-council-to-advance-next-generation-therapies-for-obesity-and-metabolic-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-establishes-metabolic-advisory-council-to-advance-next-generation-therapies-for-obesity-and-metabolic-disorders</guid>
      <pubDate>Tue, 20 Jan 2026 08:00:00 GMT</pubDate>
      <description>Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces the formation of a Metabolic Advisory Council comprising world-leading industry experts to provide scientific, clinical, and strategic guidance as Nxera advances its rapidly growing pipeline of next-generation therapies t</description>
    </item>
    <item>
      <title>Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-reports-positive-results-from-phase-3-trial-of-daridorexant-in-south-korea</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-reports-positive-results-from-phase-3-trial-of-daridorexant-in-south-korea</guid>
      <pubDate>Mon, 19 Jan 2026 09:02:00 GMT</pubDate>
      <description>Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)Nxera plans to submit a marketing authorization application for daridorexant in South Korea in the first q</description>
    </item>
    <item>
      <title>Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-usdollar36-million-in-milestone-payment-pursuant-to-research-collaboration-with-centessa</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-to-receive-usdollar36-million-in-milestone-payment-pursuant-to-research-collaboration-with-centessa</guid>
      <pubDate>Tue, 13 Jan 2026 08:09:00 GMT</pubDate>
      <description>Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. This milestone triggers a payment of US$3.6 million to Nxera pursuant to its research collaboration</description>
    </item>
    <item>
      <title>Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals</title>
      <link>https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-licenses-japan-and-select-asia-pacific-rights-to-vamorolone-for-duchenne-muscular-dystrophy-from-santhera-pharmaceuticals</link>
      <guid isPermaLink="true">https://6ix.com/company/nxera-pharma-co-ltd/news/nxera-pharma-licenses-japan-and-select-asia-pacific-rights-to-vamorolone-for-duchenne-muscular-dystrophy-from-santhera-pharmaceuticals</guid>
      <pubDate>Thu, 08 Jan 2026 07:48:00 GMT</pubDate>
      <description>Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew five-year data on vamorolone highlighted substantially improved safety profile with reduced vertebral fractures, lower incidence of cataracts and that normal growth rate was maintained. With adverse effects being a key limitation of conventional corticosteroid therapy, vamorolone’s safety profile combined its comparable effectiveness, has the potential</description>
    </item>
  </channel>
</rss>